scholarly journals Generation of a novel affibody molecule targeting Chlamydia trachomatis MOMP

2021 ◽  
Vol 105 (4) ◽  
pp. 1477-1487
Author(s):  
Mingyang Li ◽  
Wei Shi ◽  
Jia Yang ◽  
Qi Wang ◽  
Haiyan Dong ◽  
...  
Keyword(s):  
Chlamydia Trachomatis ◽  
Target Therapy ◽  
Protein A ◽  
Immunofluorescence Assay ◽  
Target Cells ◽  
Affinity Ligands ◽  
Sexually Transmitted ◽  
Affibody Molecule ◽  
Z Domain ◽  
Phage Displayed Peptide Library

Abstract Chlamydia trachomatis (C. trachomatis) is the leading cause of preventable blindness worldwide and the most prevalent cause of bacterial sexually transmitted diseases. At present, there is no available vaccine, and recurrences after antibiotics treatment are substantial problems. Major outer membrane protein (MOMP) accounts for 60% of the outer mass of C. trachomatis, functioning as trimeric porin, and it is highly antigenic. Therefore, MOMP is the most promising candidate for vaccine developing and target therapy of Chlamydia. Affibody, a new class of affinity ligands derived from the Z-domain in the binding region of Staphylococcus aureus protein A, has been the focus of researchers as a viable alternative to antibodies. In this study, the MOMP-targeted affibody molecule (ZMOMP:461) was screened by phage-displayed peptide library. Further, the affinity and specificity were characterized by surface plasmon resonance (SPR) and Western blot. Immunofluorescence assay (IFA) indicated that the MOMP-binding affibody could recognize native MOMP in HeLa229 cells infected C. trachomatis. Immunoprecipitation assay confirmed further that ZMOMP:461 molecule specifically recognizes the epitope on relaxed trimer MOMP. Our findings provide strong evidence that affibody molecule (ZMOMP:461) serves as substitute for MOMP antibody for biological applications and has a great potential for delivering drugs for target therapy. Key points • We screened a novel affibody molecule ZMOMP:461 targeting Chlamydia trachomatis MOMP. • ZMOMP:461 recognizes the recombinant and native MOMP with high affinity and specificity. • ZMOMP:461 could be internalized into live target cells.

scholarly journals Investigating the Epidemiology of Repeat Chlamydia trachomatis Detection after Treatment by Using C. trachomatis OmpA Genotyping

2014 ◽  
Vol 53 (2) ◽  
pp. 546-549 ◽  
Author(s):  
Richa Kapil ◽  
Christen G. Press ◽  
M. Lisa Hwang ◽  
LaDraka Brown ◽  
William M. Geisler
Keyword(s):  
Chlamydia Trachomatis ◽  
Sexual Partner ◽  
Protein A ◽  
Genotype Distribution ◽  
Gene Encoding ◽  
Content Type ◽  
Sexually Transmitted ◽  
Infection Treatment ◽  
Outer Membrane Protein A

RepeatChlamydia trachomatisdetection frequently occurs within months afterC. trachomatisinfection treatment. The origins of such infection (persistence versus reinfection from untreated or new partners) are varied and difficult to determine.C. trachomatisstrains can be differentiated by sequencing theompAgene encoding the outer membrane protein A (OmpA). We used OmpA genotyping to investigate the epidemiology of repeatC. trachomatisdetection after treatment inC. trachomatis-infected subjects seen at a sexually transmitted diseases clinic. Subjects were enrolled, tested forC. trachomatis, treated with azithromycin, and scheduled for a 6-month follow-up for repeatC. trachomatistesting. OmpA genotyping was performed onC. trachomatis-positive urogenital specimens obtained from patients at enrollment and follow-up. The enrollment visit OmpA genotypes forC. trachomatiswere determined for 162 subjects (92% female, 94% African American).C. trachomatiswas detected at follow-up in 39 subjects (24%). The OmpA genotype distribution at enrollment did not differ in those with versus those without repeatC. trachomatisdetection. Of the 35 subjects withC. trachomatisstrains genotyped at enrollment and follow-up, 7 (20%) had the sameompAsequence at both visits, while 28 (80%) had discordant sequences. A new sexual partner was reported more often in subjects with discordantC. trachomatisstrains than in those with concordant strains (13 [46%] versus 1 [14%];P= 0.195). Half of the subjects with discordantC. trachomatisstrains who reported sexual activity since treatment denied a new sexual partner; 62% of these subjects reported that their partner was treated. Our study demonstrates that most repeatC. trachomatisdetections after treatment were new infections with a differentC. trachomatisstrain rather than reinfection with the same strain. OmpA genotyping can be a useful tool in understanding the origins of repeatC. trachomatisdetection after treatment.

scholarly journals Bioactive Compounds of Nigella sativa Essential Oil as Antibacterial Agents against Chlamydia trachomatis D

2019 ◽  
Vol 7 (9) ◽  
pp. 370
Author(s):  
Mosolygó ◽  
Mouwakeh ◽  
Hussein Ali ◽  
Kincses ◽  
Mohácsi-Farkas ◽  
...  
Keyword(s):  
Chlamydia Trachomatis ◽  
Essential Oil ◽  
Quantitative Pcr ◽  
Bioactive Compounds ◽  
Hela Cells ◽  
Antimicrobial Agents ◽  
Nigella Sativa ◽  
Immunofluorescence Assay ◽  
Minimum Concentration ◽  
Sexually Transmitted

Urogenital tract infection caused by obligate intracellular bacterium Chlamydia trachomatis D (CtrD) is a leading cause of sexually transmitted diseases. Essential oil (EO) of Nigella sativa has a broad antimicrobial spectrum. The aim of this study was to evaluate the antimicrobial activity of the bioactive compounds (p-cymene, thymoquinone, carvacrol, and thymol) of N. sativa EO against CtrD. The cytotoxic effects of the compounds were determined by MTT assay. In order to quantify the anti-chlamydial activity of the compounds, HeLa cells were infected with CtrD or CtrD treated previously with the compounds. The titer of the infectious CtrD was determined by indirect immunofluorescence assay. The minimum inhibitory concentrations of the compounds were evaluated by direct quantitative PCR. None of the compounds showed a cytotoxic effect on HeLa cells in the concentrations tested. According to the immunofluorescence assay, all of the compounds significantly inhibited the growth of CtrD. The quantitative PCR revealed that the minimum concentration that exerted anti-chlamydial activity was 3.12 µM in the case of thymoquinone and p-cymene, while that of carvacrol and thymol was 6.25 µM. Therefore, it can be concluded that bioactive compounds of N. sativa EO could be used as effective antimicrobial agents against CtrD.

scholarly journals Prevalence of urogenital, anal, and pharyngeal infections with Chlamydia trachomatis, Neisseria gonorrhoeae, and Mycoplasma genitalium: a cross-sectional study in Reunion island

2021 ◽  
Vol 21 (1) ◽  
Author(s):  
A. Calas ◽  
N. Zemali ◽  
G. Camuset ◽  
J. Jaubert ◽  
R. Manaquin ◽  
...  
Keyword(s):  
Chlamydia Trachomatis ◽  
Neisseria Gonorrhoeae ◽  
Mycoplasma Genitalium ◽  
Cross Sectional Study ◽  
Sectional Study ◽  
Transmitted Infection ◽  
Cross Sectional ◽  
Sexually Transmitted ◽  
Urogenital Infection ◽  
High Prevalence

Abstract Background Recommendations for sexually transmitted infection (STI) screening vary significantly across countries. This study evaluated the prevalence of urogenital and extragenital infections with Chlamydia trachomatis (CT), Neisseria gonorrhoeae (NG), and Mycoplasma genitalium (MG) in patients visiting a French STI clinic in the Indian Ocean region to determine whether current STI screening practices should be updated. Methods This cross-sectional study examined all patients who visited the STI clinic between 2014 and 2015. Triplex polymerase chain reaction screening for CT, NG, and MG was performed on urine, vaginal, pharyngeal, and anal specimens (FTD Urethritis Basic Kit, Fast Track Diagnostics, Luxembourg). Results Of the 851 patients enrolled in the study, 367 were women (367/851, 43.2%) and 484 were men (484/851, 56.0%). Overall, 826 urogenital specimens (826/851, 97.1%), 606 pharyngeal specimens (606/851, 71.2%), and 127 anal specimens (127/851, 14.9%) were taken from enrolled patients. The prevalence of urogenital CT and MG was high in women ≤25 years (19/186, 10.21%; 5/186, 2.69%) and in men who have sex with women ≤30 years (16/212, 7.54%; 5/212, 2.36%). Among patients with urogenital CT infection, 13.7% (7/51) had urethritis. All patients with urogenital MG infection were asymptomatic. Men who have sex with men had a high prevalence of pharyngeal CT (2/45, 4.44%) and NG (3/44, 6.81%) and a high prevalence of anal CT (2/27, 7.41%), NG (2/27, 7.40%), and MG (1/27, 3.70%). After excluding patients with concomitant urogenital infection, extragenital infections with at least 1 of the 3 pathogens were found in 20 swabs (20/91, 21.9%) taken from 16 patients (16/81, 19.7%), all of them asymptomatic. Conclusions Routine multisite screening for CT, NG, and MG should be performed to mitigate the transmission of STIs in high-risk sexually active populations.

Design of peptide affinity ligands for S-protein: a comparison of combinatorial and de novo design strategies

2013 ◽  
Vol 17 (2) ◽  
pp. 357-369 ◽  
Author(s):  
Divya Chandra ◽  
Christopher J. Morrison ◽  
James Woo ◽  
Steven Cramer ◽  
Pankaj Karande
Keyword(s):  
De Novo ◽  
Protein A ◽  
De Novo Design ◽  
Design Strategies ◽  
S Protein ◽  
Affinity Ligands ◽  
Peptide Affinity

scholarly journals 183. chlamydia Trachomatis Seroprevalence with a pgp3 Serologic Assay and Association with Pelvic Inflammatory Disease Among Women, United States, 2013–2016

2020 ◽  
Vol 7 (Supplement_1) ◽  
pp. S220-S220
Author(s):  
Gloria E Anyalechi ◽  
Damien Danavall ◽  
Brian H Raphael ◽  
Katherine E Bowden ◽  
Jaeyoung Hong ◽  
...  
Keyword(s):  
Black Women ◽  
Chlamydia Trachomatis ◽  
Pelvic Inflammatory Disease ◽  
Inflammatory Disease ◽  
White Women ◽  
Transmitted Disease ◽  
Population Level ◽  
Reproductive Age ◽  
Nucleic Acid Amplification ◽  
Sexually Transmitted

Abstract Background Chlamydia trachomatis (CT) causes pelvic inflammatory disease (PID) and other sequelae; however, these associations are not fully characterized. CT serologic assays including Pgp3 ELISA may detect prior CT infection and may better elucidate these associations. We used a serologic Pgp3 multiplex bead array assay (Pgp3MBA) to measure CT seroprevalence in reproductive-age US women and assess the association with PID. Methods We performed CT Pgp3MBA on sera collected from women 18–39 years old during the 2013–2016 cycles of the National Health and Nutrition Examination Survey (NHANES) who had available urine CT nucleic acid amplification test results. Weighted Pgp3MBA CT seroprevalence and 95% confidence intervals (95% CI) were calculated. We also determined weighted prevalence ratios (PRs) and 95% CIs of self-reported lifetime PID among women with and without detectable Pgp3MBA and other characteristics to estimate these US national statistics. Results Among 2,339 women, 1,725 (73.7%) had available sera. Of these women, 1,425 (or 93.4% of those with data) were sexually experienced and had a CT seroprevalence of 35.9% (95% CI 33.4–38.4). When weighted for US women, CT seroprevalence was 30.5% (95% CI 26.6–34.4%), ranging from 16.9% (95% CI 11.0–22.8%) among non-Hispanic Asian women to 70.2% (95% CI 62.4–78.0%) among non-Hispanic black women. PID was reported by 4.2% (95% CI 3.1–5.2) of 1,413 sexually-experienced women with PID data or an estimated 3.8% (95% CI 2.6–5.0) of US women. Among US women, estimated PID varied by Pgp3MBA status; 7.3% (95% CI 4.3–10.2) of Pgp3MBA-positive women were estimated to report PID versus 2.3% (95% CI 1.3–3.4) of Pgp3MBA-negative women (PR 3.1; 95% CI 1.7–5.9). PID prevalence did not vary by age, nor self-reported recent sexually transmitted disease among US women, but was higher among non-Hispanic black women compared to non-Hispanic white women (PR 2.2; 95% CI 1.4–3.5). Conclusion Nearly one-third of US women have had CT by Pgp3MBA, with differences by race/ethnicity. Women with prior CT had three times the reported PID prevalence of women without CT. Further serologic research may refine the population-level impact of CT prevention activities, such as recommended annual CT screening, on PID incidence, particularly among non-Hispanic black women. Disclosures All Authors: No reported disclosures

scholarly journals Chlamydia trachomatis and urogenital mycoplasms in nonconococcal urethirits in men

2010 ◽  
Vol 63 (1-2) ◽  
pp. 47-50
Author(s):  
Sonja Vesic ◽  
Jelica Vukicevic ◽  
Eleonora Gvozdenovic ◽  
Dusan Skiljevic ◽  
Slobodanka Janosevic ◽  
...  
Keyword(s):  
Chlamydia Trachomatis ◽  
Ureaplasma Urealyticum ◽  
Mycoplasma Hominis ◽  
Sexually Active ◽  
Transmitted Infection ◽  
Sexually Transmitted ◽  
Nongonococcal Urethritis ◽  
Etiological Agents ◽  
The One

Introduction. Nongonococcal urethritis is the most common sexually transmitted infection in men, with vast majority of the etiological agents such as Chlamydia trachomatis, followed by urogenital mycoplasmas. The aim of this study was to determine the prevalence of Chlamydia trachomatis, Ureaplasma urealyticum and Mycoplasma hominis in nongonococcal urethritis in men, and to examine infections associated with these agents. Material and methods. 299 sexually active, heterosexual men with nongonococcal urethritis were included into the study. Urethral samples were taken with a dacron swab placed into the urethra up to 2-3 cm. The Direct immunojluorescence tehnique was performed for identification of Chlamydia trachomatis. Ureaplasma urealyticum and Mycoplasma hominis were detected with Mycoplasma 1ST assay. Results. Chlamydia trachomatis was detected in 22.75%, Uraeplasma urealyticum in 21.08% and Mycoplasma hominis in 8.02% cases. We found no significant differences in prevalence between Chlamydia trachomatis and Ureaplasma urealyticym (p>0.05). Monoinjections were found in 51.85% with significantly higher rate (p<0.01) than associated infections (11.70%). Among associated infections, coinfection of Chlamydia trahomatis and Ureaplasma urealyticum was predominant. Association of Chlamydia trachomatis with urogenital mycoplasmas was significantly higher (p<0.05) than the one between Ureaplasma urealyticum and Mycoplasma hominis. In 36.45% patients no patogenic microorganisms were detected. Conclusion. These results confirmed the etiological role of Chlamydia trachomatis and urogenital mycoplasmas in nongonococcal urethritis with prevalence of 51.85% in monoinfections and 11.70% in associated infections. In 36.45% of cases the etiology of urethritis was not elucidated. These results suggest that more sensitive diagnostic tool should be applied when searching for the detailed etiology of nongonococcal urethritis.

scholarly journals Sfi1p has conserved centrin-binding sites and an essential function in budding yeast spindle pole body duplication

2003 ◽  
Vol 162 (7) ◽  
pp. 1211-1221 ◽  
Author(s):  
John V. Kilmartin
Keyword(s):  
Single Molecule ◽  
Protein A ◽  
Spindle Pole Body ◽  
Spindle Pole ◽  
Binding Motif ◽  
Temperature Sensitive ◽  
Pole Body ◽  
Human Proteins ◽  
Z Domain ◽  
Essential Function

Centrins are calmodulin-like proteins present in microtubule-organizing centers. The Saccharomyces cerevisiae centrin, Cdc31p, was functionally tagged with a single Z domain of protein A, and used in pull-down experiments to isolate Cdc31p-binding proteins. One of these, Sfi1p, localizes to the half-bridge of the spindle pole body (SPB), where Cdc31p is also localized. Temperature-sensitive mutants in SFI1 show a defect in SPB duplication and genetic interactions with cdc31-1. Sfi1p contains multiple internal repeats that are also present in a Schizosaccharomyces pombe protein, which also localizes to the SPB, and in several human proteins, one of which localizes close to the centriole region. Cdc31p binds directly to individual Sfi1 repeats in a 1:1 ratio, so a single molecule of Sfi1p binds multiple molecules of Cdc31p. The centrosomal human protein containing Sfi1 repeats also binds centrin in the repeat region, showing that this centrin-binding motif is conserved.

scholarly journals Prevalence of Sexually Transmitted Diseases and Transmission of HIV in Dhaka, Bangladesh

2009 ◽  
Vol 3 (1) ◽  
pp. 27-33
Author(s):  
Tahmina Shirin ◽  
Saidur Rahman ◽  
Fareha Jesmin Rabbi ◽  
Md Humayun Kabir ◽  
KZ Mamun
Keyword(s):  
Human Immunodeficiency Virus ◽  
Herpes Simplex ◽  
Chlamydia Trachomatis ◽  
Sexually Transmitted Diseases ◽  
Treponema Pallidum ◽  
Enzyme Linked Immunosorbent Assay ◽  
Sexually Transmitted ◽  
Immunodeficiency Virus ◽  
Simplex Virus

The prevalence of sexually transmitted diseases (STDs) among patients attending out patients department of Skin and Venereal diseases of Dhaka Medical College Hospital, Dhaka and Shahid Sohrawardy Hospital, Dhaka was studied. A total of 230 patients were enrolled in the study during the period of July, 2006 to May, 2007. Urethral and endocervical swabs were collected from the participants for detection of Neisseria gonorrheae (by culture), Chlamydia trachomatis (by immunochromatoghraphy) and blood samples for the detection of Treponema pallidum antibody (by rapid plasma regain and Treponema pallidum haemagglutination assay), Herpes simplex virus type 2 antibody (both IgM and IgG by enzyme linked immunosorbent assay) and Human Immunodeficiency virus antibody (by enzyme linked immunosorbent assay). Socio-demographic data and data regarding high-risk sexual behavior were also collected. Out of 230 participants, 199 (86.5%) were positive for STDs pathogens studied, among them, 98 (42.6%) were infected with single pathogen and 101 (43.9%) were suffering from multiple infections. The prevalences of N. gonorrheae, C. trachomatis, T. pallidum, and HSV type 2 were 90 (39.1%), 110 (47.8%), 28 (12.2%) and 88 (38.2%) respectively. However, none of them were positive for HIV infection. Use of condom was significantly associated with protection of the participants against STDs. Keywords: Sexually Transmitted Diseases, Neisseria gonorrhoeae, Chlamydia trachomatis, Treponema pallidum, Herpes simplex virus type-2, Human Immunodeficiency virus   doi: 10.3329/bjmm.v3i1.2968 Bangladesh J Med Microbiol 2009; 03 (01): 27-33

Sign in / Sign up

Export Citation Format

Share Document